Neurological manifestations of the antiphospholipid syndrome;Manifestaciones neurológicas en el síndrome antifosfolipídico

Medicina Clinica

Volumn 124, Issue 16, 2005, Pages 630-633

  Suárez Álvarez, Luisa ^a   Hughes, Graham R V ^b   Khamashta, Munther A ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Headache; Multiple sclerosis; Stroke; Transverse myelitis

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CHOREA; COGNITIVE DEFECT; EPILEPSY; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; OPTIC NERVE DISEASE; PATHOGENESIS; PERCEPTION DEAFNESS; PSYCHOSIS; REVIEW; STROKE;

EID: 20344375764     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074395     Document Type: Review

References (67)

1. Hughes GRV. Migraine, memory loss, and «multiple sclerosis». Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J. 2003;79:81-3.
2. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br Med J. 1983;287:1088-9.
3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-11.
4. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GRV. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42:200-13.
5. Monereo A, Lahoz C, Khamashta MA, Arribas JR, Arnalich F. Anticuerpos anfifosfolípido. Rev Clin Esp. 1988;183:478-84
6. Cuadrado MJ, Khamashta MA, Hughes GRV. Sticky blood and headache. Lupus. 2001;10:392-3.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Anthiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
8. Sastre-Garriga J, Montalbán X. APS and the brain. Lupus. 2003;12:877-82.
9. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz L, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurological events. Neurology. 1998;50:1433-40.
10. Tietjen GE. Migraine and antiphospholipid antibodies. Cephalalgia. 1992;12:67.
11. Tzourio C, Kittner SJ, Bousser MG, Alperovitch A. Migraine and stroke in young women. Cephalalgia. 2000;20:190-9.
12. Hering R, Couturier EG, Asherson RA, Steiner TJ. Anticardiolipin antibodies in cluster headache. Cephalalgia. 1991;11:101-2.
13. Sanna G, Cuadrado MJ, Nurchis P, Khamashta MA, Mathieu A, Hughes GRV. Prevalence of headache and relationship with the presence of antiphospholipid antibodies in patients with systemic lupus erythematosus. J Autoimmun. 2000;15:P177.
14. Cuadrado MJ, Khamashta MA, Hughes GRV. Migraine and stroke in young women. Q J Med. 2000;93:317-8.
15. Cuadrado MJ, Khamashta MA, D'Cruz D, Hughes GRV. Migraine in Hughes syndrome - heparin as a therapeutic trial? Q J Med. 2001;94:114-5.
16. Hughes HRV, Cuadrado MJ, Khamashta MA, Sanna G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus. 2001;10:778.
17. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11:36-8.
18. Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21:251-64.
19. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997;3:377-86.
20. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728-34.
21. Menon S, Jameson- Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735-41.
22. Inzelberg R, Korczyn AD. Lupus anticoagulant and the late onset seizures. Acta neurol Scand. 1989;79:114-8.
23. Sokol DK, McIntyre JA, Wagenknecht DR, Dropcho EJ, Patel H, Salanova V, et al. Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy. Neurology. 2004;62:517-8.
24. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37:568-71.
25. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med. 1997;103:33-7.
26. Peltola JT, Haapala A, Isojarvi JI, Auvinen A, Palmio J, Latvala K, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med. 2000;109:712-7.
27. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10-year follow-up of 52 patients. Lupus. 1998;7:3-6.
28. Knic-Barrie S, Reister O'Connor C, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med. 1997;157:2101-8.
29. Forastiero RR, Falcon C, Rodrigues S, Kordich LC, Carreras L. Anticuerpos antifosfolípido e infarto cerebral isquémico en un niño de 6 años. Sangre (Barc). 1993;38:147-9.
30. Fullerton HJ, Von Scheven E. Back to school on APS. Rethinking the risk of recurrent stroke in children. Neurology. 2004;62:172-3.
31. Antiphospholipid Antibodies in Stroke Study (APASS) group. Anticardiolipine antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-73.
32. Brey RL, Hart RG, Sherman DG, Tegeler CT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990;40:1190-6.
33. Asherson RA, Khamashta MA, Gil A, Vázquez JJ, Chan O, Baguly E, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease and the primary antiphospholipid syndrome. Am J Med. 1989;86:391-9.
34. Levine SR, Deegan MJ, Futrell N, Wekch KM. Cerebrovascular and neurological disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181-9.
35. Coull MB, Levine SR, Brey RL. The role of antiphospholipid antibodies and stroke. Neurol Clin. 1992;10:125-43.
36. Levine SR, Brey RL, Salowich-Palm L, Sawaya KL, Havstad S. Antiphospholipid antibody associated stroke: prospective assessment of recurrent event risk. Stroke. 1993;24:188-204.
37. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke. 1997;28:1660-5.
38. Alarcón-Segovia D, Deleze M, Oria CV, Sánchez-Guerrero J, Gómez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989;68:353-65.
39. Del Papa N, Guidali L, Sala A, Buccelati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum. 1997;40:551-61.
40. Del Papa N, Raschi ER, Catelli L, Khamashta MA, Ichikawa K, Tincani A, et al. Endothelial cells as target for antiphospholipid antibodies: role of anti-beta-2-glycoprotein 1 antibodies. Am J Reprod Immunol. 1997;38:212-7.
41. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990;335:1541-4.
42. Khamashta MA, Cuadrado MJ, Mujic M, Taub N, Hunt B, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-7.
43. Derksen RHWM, De Groot PG, Kappelle LJ. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology. 2003;61:111-4.
44. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-51.
45. Levine SR, Brey RL, Tilley BC, Thompon JL, Sacco RL, Sciacca RR, et al APASS investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-84.
46. Ruiz-Irastorza G, Khamashta M, Hughes G. Letter in reply to «antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke». JAMA. 2004;291:2701-3.
47. Descheins MA, Conard J, Horellou MH, Ameri A, Preter M, Chenchu F, et al. Coagulations studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis. Stroke. 1996;27:1724-30.
48. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Neurology. 1997;28:2363-9.
49. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120-4.
50. Hummers LK, Krishnan C, Casciola-Rosen L, Rosen A, Morris S, Mahoney A, et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology. 2004;62:147-9.
51. D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004;31:280-5.
52. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GRV. Can neurologic manifestation of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79:57-68.
53. Ijdo JW, Coni-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, et al. Antiphospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 1999;8:109-15.
54. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple tions: do they represent a new nosological entity? Ann NeurOl. 1998;44:629-34.
55. Asherson RA, Hughes GRV. Antiphospholipid antibodies and chorea. J Rheumatol. 1988;15:377-9.
56. Herd JK, Medhi M, Uzedoski DM, Saldivar VA. Chorea associated with systemic lupus erythematosus: report of two cases and review of the literature. Pediatrics. 1978;61:308-15.
57. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinic and recent literature. Medicine (Baltimore). 1997;76:2197-9.
58. Cordeiro MF, Lloyd ME, Spalton DJ, Hughes GRV. Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 1994;57:1142-3.
59. Orefice G, De Joanna G, Coppola M, Brancaccio V, Ames PR. Benign intracranial hypertension: a non-thrombotic complication of the primary antiphospholipid syndrome? Lupus. 1995;4:324-6.
60. Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol. 1998;55:817-20.
61. Turkel SB, Miller JH, Reiff A. Case series: neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J Acad Child Adolesc Psychiatry. 2001;40:482-5.
62. Schwatz M, Rochas M, Welter B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59:20-3.
63. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:983-92.
64. Tumiati B, Casoli P. Sudden sensorioneural hearing loss and anticardiolipin antibody. Am J Otolaryngol. 1995;16:220.
65. Toubi E, Ben-David J, Kesse A, Podoshin L, Golan TD. Autoimmune aberration in sudden sensorineural hearing loss: association with anticardiolipin antibodies. Lupus. 1997;6:540-2.
66. Naarendorp M, Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies. J Rheumatol. 1998;25:589-92.
67. Harris EN, Englert H, Derue G, Hughes GRV, Gharavi A. Antiphospholipid antibodies in acute Guillain-Barré syndrome. Lancet. 1983;2:1361-2.